(Q46553509)

English

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

scientific article published in July 2008

In more languages
default for all languages
No label defined

No description defined

Statements

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks (English)
AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit